Asp et al. [127] investigated whether cachexia was a cause or a consequence of insulin resistance in cancer; they concluded that in C26 tumor-bearing mice, insulin resistance is an early event preceding the onset of skeletal muscle atrophy and that treatment with the insulin sensitizer rosiglitazone alleviated early cachectic features [127]. The gene discussed is INS; the disease is Insulin resistance.